Inflammatory Bowel Disease

Key Points

  • IBD encompasses two chronic autoimmune disorders: ulcerative colitis (UC) and Crohn’s disease (CD).
  • UC affects only the mucosa/submucosa of the large intestine in a uniform pattern; CD can affect all GI tract layers anywhere from mouth to anus with skip lesions.
  • Common manifestations include diarrhea, abdominal pain, weight loss, fever, and extraintestinal signs (joint, eye, skin).
  • Treatment follows a stepwise approach: aminosalicylates → corticosteroids → immunomodulators/biologics → surgery.
  • Both UC and CD are chronic, relapsing disorders associated with increased long-term GI cancer risk.

Pathophysiology

IBD involves chronic autoimmune-driven mucosal inflammation of the GI tract. The exact trigger is unknown but may involve normal intestinal bacteria, certain drugs or toxins, or infectious processes acting on a genetically susceptible host. Risk patterns include family history, age 15-30 or over 60, and higher prevalence in Northern European/Jewish ancestry, developed countries, and colder climates.

In UC, inflammation begins in the rectum and spreads uniformly upward through the colon, affecting only the mucosa and submucosa. The colon eventually becomes inflexible and shortened, losing its haustra folds. Ulcerations bleed, and stools often contain blood and mucus.

In CD, inflammation starts as singular lesions and deepens into full-thickness ulcerations. The hallmark is skip lesions — inflamed segments separated by normal bowel. The cobblestone appearance results from deep fissuring. Scar tissue leads to strictures and fistulas.

Both disorders carry an increased risk for GI tract cancer and cannot be cured medically.

Classification

FeatureUlcerative ColitisCrohn’s Disease
Layers affectedMucosa and submucosa onlyAll bowel layers (transmural)
LocationLarge intestine onlyAnywhere — mouth to anus
Lesion patternUniform, continuous from rectumSkip lesions with normal segments
StoolBloody diarrhea with mucusNon-bloody diarrhea common
Pain locationLeft upper or left lower quadrantRight lower quadrant
TenesmusCommonRare
Fistulas/stricturesRareCommon complication
Weight lossRareCommon
Nausea/vomitingRareCommon

Nursing Assessment

NCLEX Focus

Identify early signs of acute flare — bloody diarrhea, fever, tachycardia, and signs of dehydration — and escalate for fluid and electrolyte management.

  • Assess stool character, frequency, and presence of blood or mucus.
  • Assess for signs of dehydration: tachycardia, hypotension, dry mucous membranes, poor skin turgor.
  • Assess for fever and markers of systemic infection.
  • Assess nutritional status, weight trend, and albumin level.
  • Assess for anal fistulas, abscesses, rectal prolapse (more common in CD).
  • Assess for extraintestinal manifestations: joint pain, eye redness, skin rash, canker sores, and hepatobiliary involvement.

Diagnostics:

  • CBC: anemia from blood loss, elevated WBC (inflammation), elevated platelets in CD (DVT/PE risk)
  • Comprehensive metabolic panel: decreased albumin (malnutrition), electrolyte imbalances
  • Inflammatory markers: elevated CRP and ESR
  • Stool studies: fecal calprotectin elevation; rule out ova, parasites, and C. difficile
  • Endoscopy with biopsy (commonly colonoscopy; EGD in selected cases): gold standard for confirming IBD
  • Barium studies: support pattern recognition (UC “lead pipe” appearance vs CD skip lesions)
  • Ultrasound, abdominal X-ray, CT, or MRI: assess for strictures, fistulas, perforation, and bowel obstruction

Nursing Interventions

  • Monitor fluid and electrolyte balance closely during acute flares.
  • Coordinate nutritional support — enteral nutrition or TPN may be needed in severe cases.
  • Implement skin care and perianal protection when diarrhea is frequent.
  • Encourage hydration (commonly about 2 L/day if not contraindicated) and track intake/output with stool burden.
  • Encourage surveillance colonoscopy (about every 1-2 years in high-risk chronic disease) because colorectal cancer risk is increased.
  • Educate on infection prevention and vaccine adherence — immunosuppressive therapy increases infection risk.
  • Teach stress reduction strategies and trigger avoidance.
  • Refer to mental health care and peer-support resources when anxiety or depression burden is high.
  • Prepare and support patients undergoing colonoscopy or surgical procedures.
  • Provide focused teaching: avoid nsaids, report medication adverse effects promptly, recognize perforation warning symptoms, and use individualized food triggers (often limiting dairy, caffeine, alcohol, and high-fat/high-fiber foods during flares while maintaining high-protein/high-calorie/vitamin intake).

Toxic Megacolon

Severe UC can progress to toxic megacolon — non-obstructive colonic dilation with systemic toxicity. Assess for abdominal distension, fever, and tachycardia. This is a surgical emergency.

Perforation Or Obstruction

Escalate urgently for worsening abdominal pain/distension, fever, tachycardia, hypotension, or peritoneal signs that may indicate perforation, obstruction, or peritonitis.

Pharmacology

Medication therapy follows a stepwise approach:

StepDrug ClassExamplesKey Nursing Points
Step 1AminosalicylatesMesalamineAnti-inflammatory; used for mild-moderate UC
Step 2CorticosteroidsPrednisone, budesonideFor flares; taper to prevent adrenal suppression
Step 3Immunomodulators / BiologicsAzathioprine, infliximab (anti-TNF-α)Increased infection risk; monitor CBC and LFTs
Step 4Disease-specific agentsVedolizumab (UC), ustekinumab (CD)Experimental; significant side effects

Probiotics and antidiarrheals may supplement therapy for mild symptom management.

For severe or high-risk disease, a step-down strategy may be used: start with potent therapy first, then de-escalate after symptom control.

Surgical Considerations

  • UC: Total colectomy with stoma may be required when medications fail or complications occur. It can resolve intestinal UC disease but does not cure extraintestinal manifestations.
  • CD: Surgery is complication-directed (for example strictures, fistulas, or severe localized disease) and is not a definitive cure.

Clinical Judgment Application

Clinical Scenario

A patient with known UC presents with 10 bloody diarrhea episodes per day, fever 38.9°C (102°F), heart rate 112, and abdominal distension.

  • Recognize Cues: High-frequency bloody diarrhea, fever, tachycardia, and distension in a patient with UC.
  • Analyze Cues: Signs of severe flare with possible progression toward toxic megacolon.
  • Prioritize Hypotheses: Fluid/electrolyte imbalance and infection risk are immediate concerns.
  • Generate Solutions: IV fluid resuscitation, NPO, IV corticosteroids, stool cultures, and surgical consult.
  • Take Action: Implement interventions, monitor vital signs closely, and escalate rapidly if distension worsens.
  • Evaluate Outcomes: Decreased stool frequency, resolution of fever, hemodynamic stability.

Self-Check

  1. What are the key differences between Crohn’s disease and ulcerative colitis in lesion pattern and bowel layer involvement?
  2. Why are patients on biological therapy for IBD at increased risk for infection?
  3. Which clinical findings should prompt the nurse to suspect toxic megacolon?